10X GENOMICS (Germany) Top Insiders
| 1KJ Stock | EUR 12.61 0.07 0.56% |
10X GENOMICS employs about 1.2 K people. The company is managed by 13 executives with a total tenure of roughly 91 years, averaging almost 7.0 years of service per executive, having 95.62 employees per reported executive. Examination of 10X GENOMICS's management performance can provide insight into the company performance.
| Serge Saxonov CEO Chief Executive Officer, Co-Founder, Director |
| John Stuelpnagel Chairman Independent Chairman of the Board |
10X |
10X GENOMICS Management Team Effectiveness
The company has return on total asset (ROA) of (0.0892) % which means that it has lost $0.0892 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2122) %, meaning that it generated substantial loss on money invested by shareholders. 10X GENOMICS's management efficiency ratios could be used to measure how well 10X GENOMICS manages its routine affairs as well as how well it operates its assets and liabilities.10X GENOMICS Workforce Comparison
10X GENOMICS DL is rated below average in number of employees category among its peers. The total workforce of Health Information Services industry is presently estimated at about 46,223. 10X GENOMICS holds roughly 1,243 in number of employees claiming about 2.69% of equities under Health Information Services industry.
The company has Profit Margin (PM) of (0.33) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.28) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.28. 10X GENOMICS DL Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. 10X GENOMICS DL Price Series Summation is a cross summation of 10X GENOMICS price series and its benchmark/peer.
10X GENOMICS Notable Stakeholders
A 10X GENOMICS stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as 10X GENOMICS often face trade-offs trying to please all of them. 10X GENOMICS's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting 10X GENOMICS's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Serge Saxonov | Chief Executive Officer, Co-Founder, Director | Profile | |
| John Stuelpnagel | Independent Chairman of the Board | Profile | |
| Justin McAnear | Chief Financial Officer | Profile | |
| Kimberly Popovits | Independent Director | Profile | |
| Mathai Mammen | Independent Director | Profile | |
| Bradford Crutchfield | Chief Commercial Officer | Profile | |
| Jean Philibert | Chief People Officer | Profile | |
| Benjamin Hindson | President Co-Founder, Chief Scientific Officer, Director | Profile | |
| Brad Crutchfield | Chief Commercial Officer | Profile | |
| Shehnaaz Suliman | Independent Director | Profile | |
| Eric Whitaker | General Counsel | Profile | |
| Sridhar Kosaraju | Independent Director | Profile | |
| Bryan Roberts | Independent Director | Profile |
About 10X GENOMICS Management Performance
The success or failure of an entity such as 10X GENOMICS DL often depends on how effective the management is. 10X GENOMICS management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of 10X management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the 10X management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. 10X GENOMICS operates under Health Information Services classification in Germany and is traded on Frankfurt Stock Exchange. It employs 852 people.
10X GENOMICS Workforce Analysis
Traditionally, organizations such as 10X GENOMICS use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare 10X GENOMICS within its industry.10X GENOMICS Manpower Efficiency
Return on 10X GENOMICS Manpower
| Revenue Per Employee | 405.2K | |
| Revenue Per Executive | 38.7M | |
| Net Loss Per Employee | 405.5K | |
| Net Loss Per Executive | 38.8M |
Complementary Tools for 10X Stock analysis
When running 10X GENOMICS's price analysis, check to measure 10X GENOMICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X GENOMICS is operating at the current time. Most of 10X GENOMICS's value examination focuses on studying past and present price action to predict the probability of 10X GENOMICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X GENOMICS's price. Additionally, you may evaluate how the addition of 10X GENOMICS to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |